Clinical outcomes, serum IgG changes, and follow-up observations in the treatment of anti-AChR antibody-positive generalized myasthenia gravis with Efgartigimod
Open Access
- 16 February 2026
- journal article
- research article
- Published by Springer Nature in BMC Neurology
- Vol. 26 (1)
Abstract
To investigate the clinical effects, changes in serum IgG levels, and follow-up observations following treatment with Efgartigimod in patients with anti-acKeywords
Funding Information
- Henan Provincial Science and Technology Research Project (LHGJ20240705)
- Henan Provincial Science and Technology Research Project (LHGJ20240705)
- Henan Provincial Science and Technology Research Project (LHGJ20240705)
- Henan Provincial Science and Technology Research Project (LHGJ20240705)
- Henan Provincial Science and Technology Research Project (LHGJ20240705)
- Henan Provincial Science and Technology Research Project (LHGJ20240705)
- Henan Provincial Science and Technology Research Project (LHGJ20240705)
- Henan Provincial Science and Technology Research Project (LHGJ20240705)
This publication has 29 references indexed in Scilit:
- Efficacy of multi-cycle Efgartigimod in achieving minimal symptom expression in myasthenia gravis: A comparative multi-center studyInternational Immunopharmacology, 2025
- A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patientsJournal of Neurology, 2024
- Efgartigimod for generalized myasthenia gravis: A multicenter real‐world cohort study in ChinaAnnals of Clinical and Translational Neurology, 2024
- Efgartigimod in refractory autoimmune myasthenia gravisMuscle & Nerve, 2024
- Efgartigimod infusion in the treatment regimen for myasthenic crisis: A case reportMuscle & Nerve, 2024
- Efgartigimod improves triple-negative myasthenia gravisNeurological Sciences, 2023
- Safety and outcomes with efgartigimod use for acetylcholine receptor‐positive generalized myasthenia gravis in clinical practiceMuscle & Nerve, 2023
- Utilization of MG‐ADL in myasthenia gravis clinical research and careMuscle & Nerve, 2022
- Targeting FcRn for immunomodulation: Benefits, risks, and practical considerationsJournal of Allergy and Clinical Immunology, 2020
- Minimal clinically important difference in myasthenia gravis: Outcomes from a randomized trialMuscle & Nerve, 2013